Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)

Description

This research study is studying two drugs at different time points as a possible treatment for advanced renal cell cancer The drugs involved in this study are: Nivolumab Ipilimumab

Study Start Date

September, 26 2017

Estimated Completion Date

November 2024

Interventions

  • Drug: Ipilimumab
  • Drug: Nivolumab

Study ID

Dana-Farber Cancer Institute -- 17-064

Status

Recruiting

Trial ID

NCT03203473

Study Type

Interventional

Trial Phase

Phase 2

Enrollment Quota

58

Sponsor

Dana-Farber Cancer Institute

Inclusion Criteria

  • Age ? 18 years at the time of consent.
  • ECOG Performance Status of ? 2 within 28 days prior to registration.
  • Unresectable advanced or metastatic RCC to include both clear cell and non-clear histologies.
  • Availability at the study site of formalin-fixed, paraffin-embedded (FFPE) archival tumor specimens, when available, and willingness of the subject to undergo mandatory fresh tumor biopsy prior to treatment initiation unless determined medically unsafe or not feasible. Given that fresh tumor tissue at screening is required for correlative assessments, a prior biopsy cannot take the place of the baseline mandatory biopsy.
  • The archival specimen must contain adequate viable tumor tissue.
  • The specimen may consist of a tissue block (preferred and should contain the highest grade of tumor) or at least 20 unstained serial sections. Fine-needle aspiration, brushings, cell pellet from pleural effusion, bone marrow aspirate/biopsy are not acceptable.
  • Fresh tumor biopsy at progression will be optional as detailed in study schema.
  • Previously untreated or treated subjects with no limit on prior lines of systemic therapies are allowed.
  • Measurable disease as defined by Response Evaluation Criteria In Solid Tumors RECIST 1.1 within 28 days prior to registration.
  • Demonstrate adequate organ function as defined in the table below. All screening labs to be obtained within 28 days prior to first study treatment. System Laboratory Value
  • Hematological
  • White blood cell (WBC) ? 2500 cells/µL
  • Absolute Neutrophil Count (ANC) ? 1500 cells/µL
  • Platelet count (plt) ? 100,000/ µL
  • Hemoglobin (Hgb) ? 9 g/dL
  • Absolute lymphocyte count ? 500 cells/µL
  • Renal --Serum creatinine OR Calculated creatinine clearance ? 1.5 x ULN ? 40 mL/min
  • Cockcroft-Gault formula will be used to calculate creatinine clearance
  • Hepatic and Other
  • Bilirubin ? 1.5 × upper limit of normal (ULN)
  • Aspartate aminotransferase (AST) ? 2.5 × ULN
  • Alanine aminotransferase (ALT) ? 2.5 × ULN
  • Alkaline Phosphatase ? 2.5 × ULN
  • Subjects with documented liver metastases should have AST and ALT ? 5 x ULN. Subjects with documented liver or bone metastases should have alkaline phosphatase ? 5 x ULN
  • Subjects with known Gilbert's disease should have a serum bilirubin ? 3 x ULN. --Albumin > 2.5 g/dL
  • Coagulation
  • International Normalized Ratio (INR) or Prothrombin Time (PT)
  • Activated Partial Thromboplastin Time (aPTT) ? 1.5 × ULN (unless on prophylactic or therapeutic dosing with low molecular weight heparin)
  • Females of childbearing potential must have a negative serum pregnancy test within 28 days prior to registration. NOTE: Females are considered of child bearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are naturally postmenopausal for at least 12 consecutive months.
  • Females of childbearing potential and males must be willing to abstain from heterosexual activity or to use 2 forms of effective methods of contraception from the time of informed consent until 120 days after treatment discontinuation. The two contraception methods can be comprised of two barrier methods, or a barrier method plus a hormonal method.
  • As determined by the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study.

Exclusion Criteria

  • Prior use of systemic checkpoint inhibitors for the management of metastatic RCC is excluded. Prior IFN-? or IL-2 is allowed.
  • Treatment with systemic immunosuppressive medications including but not limited to: prednisone, dexamethasone, cyclosporin, azathioprine, methotrexate, thalidomide, anti-tumor necrosis factor (TNF) agents within 2 weeks of first study dose.
  • Subjects who have received acute, low-dose systemic immunosuppressant medications may be enrolled (such as steroids for acute nausea or cancer-related pain ? 10 mg prednisone) may be enrolled sooner than 2 weeks of first study dose.
  • Subjects with adrenal insufficiency on physiologic replacement doses of steroids may be enrolled (? 10 mg prednisone).
  • The use of inhaled, topical, ocular or intra-articular corticosteroids and mineralocorticoids are allowed.
  • Treatment with a receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor (e.g. denosumab) within 2 weeks of first study dose.
  • Radiotherapy for RCC within 14 days of first study treatment with the exception of a single fraction of radiation administered for palliation of symptoms.
  • Known active metastases to the brain, spinal cord or leptomeninges unless adequately treated with radiotherapy, radiosurgery, or surgery and stable for at least 4 weeks of first study treatment as documented by magnetic resonance imaging (MRI) or computerized tomography (CT) imaging and having no ongoing requirement for steroids.
  • Malignancies other than RCC within 5 years of first study treatment with the exception of those with negligible risk of metastases or death and/or treated with expected curative outcome (carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer, ductal carcinoma in situ of the breast, non-muscle invasive urothelial carcinoma).
  • History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion protein.
  • Known hypersensitivity to any component of the nivolumab or ipilimumab product.
  • Any active or recent history (within 6 months of first study dose) of autoimmune disease or syndrome that requires systemic corticosteroids (>10 mg daily prednisone equivalent) or immunosuppressive medications including but not limited to: myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with anti-phospholipid syndrome, Wegner's granulomatosis, Sjogren's syndrome, Guillain-Barre syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. Subjects with vitiligo, controlled type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement therapy are permitted to enroll.
  • Any condition requiring treatment with corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medication within 14 days of the first dose of study drug. Inhaled, topical, ocular or intra-articular steroids and adrenal replacement steroid doses ? 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
  • Uncontrolled adrenal insufficiency.
  • History of idiopathic pulmonary fibrosis, organized pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening imaging CT of the chest. History of radiation pneumonitis in the radiation field is permitted.
  • Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome.
  • Known active or chronic hepatitis B infection (defined as having a positive hepatitis B surface antigen (HBsAg) test at screening). Subject with past or resolved hepatitis B infection (defined as having a negative HBsAg test and positive antibody to hepatitis B core antigen test) are eligible. Hepatitis B viral DNA must be obtained in subjects with positive hepatitis B core antibody prior to first treatment start.
  • Active hepatitis C infection. Subjects positive hepatitis C antibody test are eligible if PCR is negative for hepatitis C viral DNA.
  • Severe infections within 4 weeks of first study treatment including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia.
  • Signs and symptoms of infection within 2 weeks of first study treatment. Receipt of therapeutic oral or IV antibiotics within 2 weeks of first study treatment. Subjects receiving routine antibiotic prophylaxis (for dental extractions/procedures) are eligible.
  • Significant cardiovascular disease such as New York Heart Association (NYHA) class III or greater, myocardial infarction within the previous 3 months, unstable arrhythmias, unstable angina. Patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or left ventricular ejection fraction < 45% must be on a stable regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist when appropriate.
  • Prolonged corrected QT interval by the Fridericia correction formula (QTcF) on screening EKG > 480 msec.
  • History of abdominal or tracheoesophageal fistula or GI perforation within 6 months of first study treatment.
  • Clinical signs or symptoms of GI obstruction or requirement of routine parenteral nutrition or tube feedings.
  • Evidence of abdominal free air not explained by paracentesis or recent surgical procedure.
  • Serious, non-healing or dehiscing wound or active ulcer.
  • Major surgical procedure within 4 weeks of first study treatment.
  • Presence of any toxicities attributed to prior anti-cancer therapy that are not resolved to grade 1 (National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0) or baseline before administration of study drug.
  • Prior allogenic stem cell or solid organ transplant.
  • Administration of a live, attenuated vaccine within 4 weeks for first study treatment.

Gender

All

Ages

18 Years and older

Accepts Healthy Volunteers

No

Study Locations and Contact Information (8)

Study Location Distance Name Phone Email
Beth Israel Deaconess Medical Center - Boston, Massachusetts 2.6 miles David F McDermott MD 617-632-9250 None
Dana Farber Cancer Institute - Boston, Massachusetts 2.6 miles Lauren C Harshman MD 617-632-4524 LaurenC_Harshman@DFCI.HARVARD.EDU
Beth Israel Deaconess Medical Center - Boston, Massachusetts 2.6 miles David F McDermott MD 617-632-9250 None
Dana Farber Cancer Institute - Boston, Massachusetts 2.6 miles Lauren C Harshman MD 617-632-4524 LaurenC_Harshman@DFCI.HARVARD.EDU
Beth Israel Deaconess Medical Center - Boston, Massachusetts 2.6 miles David F McDermott MD 617-632-9250 None
Dana Farber Cancer Institute - Boston, Massachusetts 2.6 miles Lauren C Harshman MD 617-632-4524 LaurenC_Harshman@DFCI.HARVARD.EDU
Beth Israel Deaconess Medical Center - Boston, Massachusetts 2.6 miles David F McDermott MD 617-632-9250 None
Dana Farber Cancer Institute - Boston, Massachusetts 2.6 miles Lauren C Harshman MD 617-632-4524 LaurenC_Harshman@DFCI.HARVARD.EDU

ClinicalTrialsLocator.com provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from ClinicalTrials.gov. This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.